Objectives: The objective of the study is to evaluate the effectiveness of Zal-trap 0.125 mg and to identify its side effects in patients resistant to Avastin. Study Design: In this quasi-experimental interventional study, the total sample volume is calculated to be 17 patients. The control group is the preoperative status of the patients and no randomization is performed. Method: In a sterile manner, 0.05 ml zal-trap is injected into the Vitreous humour of the eye with a lower visual acuity (visual acuity less than 20/100) in patients with retinal vascular disorders (AMD, DME, and RVO) who require anti-VEGF treatment and have not responded to Avastin, after obtaining informed consent. The visual acuity of the patients will be monitored in the beginning of the study and 1 week and 1 month after the procedure. Participants: The inclusion criteria are eyes with AMD or active neovascular DME, best corrected visual acuity of 20/100 (06/30) or less, capability of comprehending the advantages and risks of the study, ability to sign the informed consent form, and lack of response to Avastin treatment. The exclusion criteria of the study are the signs of ocular infection, and a positive history of MI or CVA. Interventions: After applying local anesthesia and povidone-iodine, a sterile eyelid retractor will be used. In “one” eye of the patient, 0.05 ml (1.25 mg) Zal-trap that is already prepared from a 4ml vial is injected using a 30-gauge 1cc syringe. Main outcome variables including primary and secondary outcomes are visual acuity of the patients and the height of retinal pigment epithelial detachment, respectively.